Advances of Researches on the Role of Histone Modification in Hematological Neoplasms.
10.7534/j.issn.1009-2137.2015.04.054
- Author:
Fang SUN
1
;
Yun PAN
2
;
Yan LI
3
Author Information
1. Department of Pathology, College of Basic Medicine, DaLi University, Dali 671000, Yunnan Province, China.
2. Department of Pathology, Affiliated Hospital of Dali University, Dali 671000, Yunnan Province, China.
3. Department of Pathology, College of Basic Medicine, DaLi University, Dali 671000, Yunnan Province, China. E-mail: bigbigsmile04@gmail.com.
- Publication Type:Journal Article
- MeSH:
Cell Transformation, Neoplastic;
Epigenesis, Genetic;
Hematologic Neoplasms;
Histone Deacetylase Inhibitors;
Histone-Lysine N-Methyltransferase;
Histones;
Humans
- From:
Journal of Experimental Hematology
2015;23(4):1184-1189
- CountryChina
- Language:Chinese
-
Abstract:
As a crucial part of epigenetic regulation, the histone modification catalyzed by histone modification enzymes can alter the chromatin structure and modulate the gene expression. The role of histone modification in disease pathogenesis, especially in tumorigenesis, has become a research hotspot. The deregulation of histone modification, such as the overexpression and gain-of-function mutations of histone methyltransferase EZH2, the inactive mutations of histone methyltransferase MLL2, histone acetyltransferase CREBBP and EP300 are crucial for the development of hematological neoplasms. Some of Epi-drugs such as HDAC inhibitors, EZH2 inhibitors, are already clinically used, some are still in basic research stage, which are important field of new drug development for hematological neoplasms. In this review, the researches advances of basic medical sciences and clinical applications of aberrant histone modifications in hematological neoplasms are summarized.
